LEVALBUTEROL HYDROCHLORIDE

Post-LOE

levalbuterol

Teva

ANDAINHALATIONSOLUTION

Approved

Dec 2016

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

2/8 — Basic

LEVALBUTEROL HYDROCHLORIDE (levalbuterol) by Teva is 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3′, 5′-adenosine monophosphate (cyclic amp). First approved in 2016.

Drug data last refreshed 18h ago

Mechanism of Action

2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular concentration of cyclic-3′, 5′-adenosine monophosphate (cyclic AMP). The increase in cyclic AMP is associated with the activation of protein kinase A, which in turn…

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Company

Worked on LEVALBUTEROL HYDROCHLORIDE at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.